

Osimertinib ADAURA

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Osimertinib ADAURA

FINAL SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE



Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Thoracic Malignancies  
Therapeutic Indication: Adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIa NSCLC whose tumours have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations  
Experimental Arm: Osimertinib  
Control Arm: Placebo



